Silymarin alleviates bleomycin-induced pulmonary toxicity and lipid peroxidation in mice

Figures & data

Table 1. Effects of silymarin on pulmonary oxidative parameters following bleomycin exposure.

Groups	MDA (nmol/mg protein)	GSH (µmol/g lung)	GST (nmol/min/mg protein)	Catalase (µmol/min/ml protein)
Control	0.14 ± 0.01	3.3 ± 0.4	48.2 ± 3.5	71.9 ± 3.5
BLM	0.27 ± 0.02^a	1.8 ± 0.2^a	32.4 ± 2.8^a	51.5 ± 3.1^a
BLM + Silymarin 50	0.19 ± 0.02^b	2.6 ± 0.4^b	38 ± 3.3	60.0 ± 4.8
BLM + Silymarin 100	0.17 ± 0.01^b	3.1 ± 0.2^b	41 ± 2.6^b	65.7 ± 2.5^b

Data are presented as means ± SD (n = 7 mice/group). BLM, bleomycin.

^ap < 0.05 versus control group.

^bp < 0.05 versus BLM group.

Figure 1. Effect of silymarin on pulmonary MPO activity in bleomycin-exposed mice. BLM, bleomycin. MPO activity is expressed as U min/mg of protein. Results are mean ± SD for 7 mice/group. ^ap < 0.05 versus control group. ^bp < 0.05 versus BLM group.

Figure 2. Effects of silymarin in serum tumor necrosis factor-alpha (TNF-α) level in animal exposed to bleomycin. BLM, bleomycin. Results are mean ± SD for 7 mice/group. ^ap < 0.05 versus control group. ^bp < 0.05 versus BLM group.

Figure 3. Effects of silymarin treatment in serum interleukin-6 (IL-6) level in mice exposed to bleomycin. BLM, bleomycin. Results are mean ± SD for 7 mice/group. ^ap < 0.05 versus control group. ^bp < 0.05 versus BLM group.